Legal Advantage Investments Inc. Has $2.30 Million Holdings in GRAIL, Inc. $GRAL

Legal Advantage Investments Inc. lifted its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 32.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,500 shares of the company’s stock after acquiring an additional 11,000 shares during the period. Legal Advantage Investments Inc. owned approximately 0.11% of GRAIL worth $2,300,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. N.E.W. Advisory Services LLC bought a new position in GRAIL during the 4th quarter worth about $26,000. Comerica Bank lifted its holdings in shares of GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of GRAIL during the fourth quarter worth about $28,000. Elyxium Wealth LLC acquired a new position in shares of GRAIL during the fourth quarter worth about $31,000. Finally, Intesa Sanpaolo S.p.A. bought a new position in shares of GRAIL during the fourth quarter worth about $44,000.

GRAIL Trading Down 1.6%

Shares of GRAL opened at $61.11 on Wednesday. The company’s fifty day simple moving average is $59.70 and its 200 day simple moving average is $72.14. GRAIL, Inc. has a 1-year low of $29.95 and a 1-year high of $118.84. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -5.89 and a beta of 3.15.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. The firm had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, research analysts forecast that GRAIL, Inc. will post -10.91 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on GRAL shares. Morgan Stanley dropped their target price on GRAIL from $110.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Mizuho initiated coverage on GRAIL in a research report on Friday, April 10th. They set a “neutral” rating and a $58.00 price target for the company. Guggenheim decreased their price target on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Tuesday, April 21st. Finally, Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $67.00.

Insider Activity

In other GRAIL news, CEO Robert P. Ragusa sold 123,502 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $6,165,219.84. Following the sale, the chief executive officer owned 518,582 shares in the company, valued at $25,887,613.44. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares in the company, valued at $10,001,117.04. This represents a 0.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 232,464 shares of company stock valued at $11,621,242. Company insiders own 1.83% of the company’s stock.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Glancy Prongay, and others, issued reminders that investors who bought GRAL between May 13, 2025 and February 19, 2026 may join the securities fraud class action, with an August 4, 2026 lead-plaintiff deadline. Article Title
• Neutral Sentiment: The lawsuits allege GRAIL misled investors about its NHS-Galleri trial results, and one filing says the February 20 trial update erased more than $2.2 billion in market value, underscoring the magnitude of the alleged disclosure issue. Article Title
• Negative Sentiment: The mounting legal announcements add to investor uncertainty and could weigh on sentiment toward GRAIL as shareholders await further developments in the class action process. Article Title

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.